Low complexity, Instrument-free for CT/NG

Information

  • Research Project
  • 7650478
  • ApplicationId
    7650478
  • Core Project Number
    U01AI082522
  • Full Project Number
    1U01AI082522-01
  • Serial Number
    82522
  • FOA Number
    RFA-AI-08-003
  • Sub Project Id
  • Project Start Date
    3/6/2009 - 15 years ago
  • Project End Date
    2/29/2012 - 12 years ago
  • Program Officer Name
    DAVID, HAGIT S.
  • Budget Start Date
    3/6/2009 - 15 years ago
  • Budget End Date
    2/28/2010 - 14 years ago
  • Fiscal Year
    2009
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/6/2009 - 15 years ago
Organizations

Low complexity, Instrument-free for CT/NG

DESCRIPTION (provided by applicant): We propose to develop a low cost, moderate complexity molecular test for the detection of CT/NG intended for use at STD clinics. This test will use a manually operated nucleic acid extraction device, an isothermal amplification technology called thermophilic helicase dependent amplification (tHDA), a disposable nucleic acid detection device, and a reusable reader. Our proprietary tHDA uses helicases to separate DNA strands rather than heat but still relies on DNA polymerase to amplify DNA instead of combinations of polymerases with other enzymes. This simple enzymology allows us to detect DNA amplification inhibitors, allows for the confirmation that a legitimate product was amplified, and the quantitation of nucleic acids in a sample. No other isothermal amplification technology retains these highly attractive features. The projected cost for the two assays is ~$20. The advantage of using isothermal amplification is that equipment costs will be minimal (i.e., $200 water bath, and a ~$800 reader). We propose to focus our first project year on further evolving our proposed assay system by improving our reaction speed, improving our prototype sample preparation module, and demonstrating the feasibility of using an automated reader with the BESt cassette. In year 2, we will focus on the formal design control process, and transfer to manufacturing of our proposed assay system. We will develop a clinical study plan for review by institutional IRBs, and a pre-IDE for review by the Food and Drug Administration (FDA). In years 3 and 4 we will perform a multi-site clinical study to obtain data for the submission of a 510(k) to the FDA. We expect to obtain FDA clearance for the CT/NG assays by the end of the proposed project. In year 5, we will develop a clinical plan, and perform a pre-clinical study to evaluate the feasibility of obtaining CLIA-waiver for the assay system.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U01
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    680347
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:680347\
  • Funding Mechanism
    Research Projects
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOHELIX CORPORATION
  • Organization Department
  • Organization DUNS
    169510950
  • Organization City
    BEVERLY
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01915
  • Organization District
    UNITED STATES